Selected article for: "active cell and acute respiratory syndrome"
Author: Chen, F; Chan, K.H; Jiang, Y; Kao, R.Y.T; Lu, H.T; Fan, K.W; Cheng, V.C.C; Tsui, W.H.W; Hung, I.F.N; Lee, T.S.W; Guan, Y; Peiris, J.S.M; Yuen, K.Y
Title: In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
  • Cord-id: ot5pvtbl
  • Document date: 2004_5_18
    • ID: ot5pvtbl
    Snippet: Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. T
    Document: Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.

    Search related documents:
    Co phrase search for related documents
    • active compound and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute viral respiratory infection: 1
    • active site and lopinavir ribavirin: 1
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and administration initial phase: 1
    • acute respiratory syndrome and administrative region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome and load viral clinical: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and load viral clinical study: 1, 2, 3
    • acute respiratory syndrome and lopinavir ribavirin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir ribavirin combination: 1, 2, 3, 4, 5, 6
    • acute viral respiratory infection and administration initial phase: 1
    • acute viral respiratory infection and load viral clinical: 1, 2
    • acute viral respiratory infection and lopinavir ritonavir: 1
    • load viral clinical and lopinavir ribavirin: 1
    • load viral clinical and lopinavir ritonavir: 1, 2, 3, 4, 5